Outlook Therapeutics (OTLK) Enterprise Value: 2015-2020
Historic Enterprise Value for Outlook Therapeutics (OTLK) over the last 6 years, with Sep 2020 value amounting to $91.6 million.
- Outlook Therapeutics' Enterprise Value rose 168.91% to $91.6 million in Q3 2020 from the same period last year, while for Sep 2020 it was $91.6 million, marking a year-over-year increase of 366.20%. This contributed to the annual value of $126.3 million for FY2024, which is 119.63% up from last year.
- Per Outlook Therapeutics' latest filing, its Enterprise Value stood at $91.6 million for Q3 2020, which was down 2.50% from $93.9 million recorded in Q2 2020.
- Outlook Therapeutics' Enterprise Value's 5-year high stood at $94.6 million during Q3 2016, with a 5-year trough of $16.4 million in Q4 2019.
- For the 3-year period, Outlook Therapeutics' Enterprise Value averaged around $50.3 million, with its median value being $42.3 million (2018).
- Its Enterprise Value has fluctuated over the past 5 years, first surged by 21,457.27% in 2016, then plummeted by 75.43% in 2020.
- Quarterly analysis of 5 years shows Outlook Therapeutics' Enterprise Value stood at $68.9 million in 2016, then plummeted by 75.25% to $17.1 million in 2017, then surged by 148.19% to $42.3 million in 2018, then tumbled by 61.18% to $16.4 million in 2019, then spiked by 168.91% to $91.6 million in 2020.
- Its Enterprise Value stands at $91.6 million for Q3 2020, versus $93.9 million for Q2 2020 and $21.3 million for Q1 2020.